Literature DB >> 23882160

Database of T cell-defined human tumor antigens: the 2013 update.

Nathalie Vigneron1, Vincent Stroobant, Benoît J Van den Eynde, Pierre van der Bruggen.   

Abstract

The plethora of tumor antigens that have been--and are still being--defined required systematization to provide a comprehensive overview of those tumor antigens that are the most relevant targets for cancer immunotherapy approaches. Here, we provide a new update of a peptide database resource that we initiated many years ago. This database compiles all human antigenic peptides described in the literature that fulfill a set of strict criteria needed to ascertain their actual "tumor antigen" nature, as we aim at guiding scientists and clinicians searching for appropriate cancer vaccine candidates (www.cancerimmunity.org/peptide). In this review, we revisit those criteria in light of recent findings related to antigen processing. We also introduce the 29 new tumor antigens that were selected for this 2013 update. Two of the new peptides show unusual features, which will be briefly discussed. The database now comprises a total of 403 tumor antigenic peptides.

Entities:  

Keywords:  CD4; CD8; HLA; T cell; database; peptide

Mesh:

Substances:

Year:  2013        PMID: 23882160      PMCID: PMC3718731     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  51 in total

1.  A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.

Authors:  Frank Neumann; Boris Kubuschok; Kubilay Ertan; Claudia Schormann; Stefan Stevanovic; Klaus-Dieter Preuss; Werner Schmidt; Michael Pfreundschuh
Journal:  Cancer Immunol Immunother       Date:  2011-06-01       Impact factor: 6.968

2.  An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Authors:  Alexandre Dalet; Paul F Robbins; Vincent Stroobant; Nathalie Vigneron; Yong F Li; Mona El-Gamil; Ken-ichi Hanada; James C Yang; Steven A Rosenberg; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

3.  A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.

Authors:  Wenbin Ma; Nathalie Vigneron; Jacques Chapiro; Vincent Stroobant; Catherine Germeau; Thierry Boon; Pierre G Coulie; Benoît J Van den Eynde
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

4.  Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.

Authors:  Ray Wilkinson; Katherine Woods; Rachael D'Rozario; Rebecca Prue; Frank Vari; Melinda Y Hardy; Ying Dong; Judith A Clements; Derek N J Hart; Kristen J Radford
Journal:  Cancer Immunol Immunother       Date:  2011-08-27       Impact factor: 6.968

5.  Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Authors:  Zhaoting Meng; Yadong Wang; Guanzhong Zhang; Yuehua Ke; Yanfeng Yan; Liangliang Wu; Qianrong Huang; Gang Zeng; Yu Wang; Han Ying; Shunchang Jiao
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

6.  Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin.

Authors:  Munehide Nakatsugawa; Kazutaka Horie; Toshiaki Yoshikawa; Manami Shimomura; Yamato Kikuchi; Noriko Sakemura; Shiro Suzuki; Daisuke Nobuoka; Yoshihiko Hirohashi; Toshihiko Torigoe; Kenji Harada; Hideo Takasu; Noriyuki Sato; Tetsuya Nakatsura
Journal:  Int J Oncol       Date:  2011-06-17       Impact factor: 5.650

7.  Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.

Authors:  Larry D Anderson; Danielle R Cook; Tori N Yamamoto; Carolina Berger; David G Maloney; Stanley R Riddell
Journal:  Cancer Immunol Immunother       Date:  2011-04-03       Impact factor: 6.968

Review 8.  Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

9.  Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.

Authors:  Weigang Wen; Lijie Zhang; Jirun Peng; Juanjuan Chen; Jiaqing Hao; Xiaofeng Li; Xiaoping Qian; Pumei Zeng; Yu Zhang; Yanhui Yin
Journal:  Cancer Sci       Date:  2011-06-27       Impact factor: 6.716

10.  Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.

Authors:  Oliver C Goodyear; Hayden Pearce; Guy Pratt; Paul Moss
Journal:  Cancer Immunol Immunother       Date:  2011-07-23       Impact factor: 6.968

View more
  68 in total

1.  Ovalbumin self-assembles into amyloid nanosheets that elicit immune responses and facilitate sustained drug release.

Authors:  Saba Tufail; Mohd Asif Sherwani; Shoaib Shoaib; Sarfuddin Azmi; Mohammad Owais; Najmul Islam
Journal:  J Biol Chem       Date:  2018-05-31       Impact factor: 5.157

2.  Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+ T cells.

Authors:  Tihana Tršan; Kristina Vuković; Petra Filipović; Ana Lesac Brizić; Niels A W Lemmermann; Kilian Schober; Dirk H Busch; William J Britt; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  Eur J Immunol       Date:  2017-07-04       Impact factor: 5.532

Review 3.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

4.  Early detection of lung cancer by using an autoantibody panel in Chinese population.

Authors:  Shengxiang Ren; Shucai Zhang; Tao Jiang; Yayi He; Zhiyong Ma; Hourong Cai; Xiaohong Xu; Yan Li; Weijing Cai; Jing Zhou; Xiaopeng Liu; Xuejun Hu; Jun Zhang; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Oncoimmunology       Date:  2017-10-16       Impact factor: 8.110

Review 5.  Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael W DeGregorio
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

6.  TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.

Authors:  Devin B Lowe; Camille K Bivens; Alexis S Mobley; Christian E Herrera; Amanda L McCormick; Timea Wichner; Manoj K Sabnani; Laurence M Wood; Jon A Weidanz
Journal:  MAbs       Date:  2017 May/Jun       Impact factor: 5.857

7.  Tumor antigenicity revealed.

Authors:  Peter A Savage
Journal:  Trends Immunol       Date:  2014-01-15       Impact factor: 16.687

8.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity.

Authors:  Preeti Sharma; Daniel T Harris; Jennifer D Stone; David M Kranz
Journal:  Cancer Immunol Res       Date:  2019-09-23       Impact factor: 11.151

9.  Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.

Authors:  Alexander S Cheung; Sandeep T Koshy; Alexander G Stafford; Maartje M C Bastings; David J Mooney
Journal:  Small       Date:  2016-03-08       Impact factor: 13.281

Review 10.  Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Authors:  Matthew M Gubin; Maxim N Artyomov; Elaine R Mardis; Robert D Schreiber
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.